Compare NOV Inc. Common Stock (NOV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NOV Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? NOV Inc. Common Stock trades at $18.66 (market cap $6.68B), while Travere Therapeutics Inc. Common Stock trades at $54.66 (market cap $5.02B). The key difference: NOV Inc. Common Stock is the larger of the two by market cap, and NOV Inc. Common Stock pays a 1.92% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NOV Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NOV | TVTX | |
|---|---|---|
Market Cap | $6.68B | $5.02B |
Volume | 4,702,090 | 2,060,842 |
Sector | Energy | Health |
52-Week High | $21.71 | $67.52 |
52-Week Low | $12.66 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.85B | $5.15B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NOV trades at $18.96, up 0.37% with a bearish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates but showing revenue decline. Valuation metrics show a high P/E ratio of 70.22 but attractive P/S of 0.81, while profitability remains weak with 1.1% net margin. Recent news highlights strong subsea demand but Middle East risks and weak equipment sales.
The outlook is cautious with analyst consensus at $21.80 target (15% upside) but technical weakness. Investment opportunity lies in energy equipment strength and margin improvements, while risks include geopolitical exposure, competitive pressures, and inconsistent earnings performance. The stock faces headwinds from capital spending constraints in the oilfield sector.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NOV Inc. Common Stock
NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
